Pulmonary Hypertension
Congress Materials – Association for European Paediatric and Congenital Cardiology (AEPC 2025)
2025 Association for European Paediatric and Congenital Cardiology | May 28-31 | Hamburg, Germany
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Efficacy and safety of selexipag in pediatric pulmonary arterial hypertension: results from the randomized controlled phase 3 SALTO study
Maurice Beghetti, Rolf M.F. Berger, Julian I. Borissoff, Simon Grill, Angela Jeong, Aneliya Rankova, Tatiana Remeňová, Shu-Fang Hsu Schmitz, Dunbar D. Ivy
Macitentan in pediatric pulmonary arterial hypertension: results from the phase 3 randomized controlled TOMORROW study
Rolf M.F. Berger, Dunbar D. Ivy, Julian I. Borissoff, Sofija Cerovic, Dénes Csonka, Tatiana Remeňová, Dominik Richard, Matthieu Villeneuve, Maurice Beghetti
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.